ORIENT BIO Inc. (KRX:002630)
South Korea
· Delayed Price · Currency is KRW 561.00
+15.00 (2.75%)
Mar 10, 2026, 9:19 AM KST
ORIENT BIO Revenue
ORIENT BIO had revenue of 17.21B KRW in the quarter ending December 31, 2021, with 21.77% growth. This brings the company's revenue in the last twelve months to 59.09B, up 19.53% year-over-year. In the fiscal year ending March 31, 2021, ORIENT BIO had annual revenue of 52.02B with 39.79% growth.
Revenue (ttm)
59.09B
Revenue Growth
+19.53%
P/S Ratio
1.10
Revenue / Employee
472.73M
Employees
125
Market Cap
64.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2021 | 52.02B | 14.81B | 39.79% |
| Mar 31, 2020 | 37.21B | 6.84B | 22.52% |
| Mar 31, 2019 | 30.37B | 4.75B | 18.53% |
| Mar 31, 2018 | 25.62B | -83.39B | -76.50% |
| Mar 31, 2017 | 109.02B | 3.97B | 3.78% |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
| Mar 31, 2014 | Pro | Pro | Pro |
| Mar 31, 2013 | Pro | Pro | Pro |
| Mar 31, 2012 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Oncocross | 884.68M |
| GeneOne Life Science | 30.90B |
| Amicogen | 87.97B |
| IMB Dx | 4.26B |
| CG Invites | 18.12B |
| ENCell | 5.91B |
| Macrogen | 179.98B |
| Xcell Therapeutics | 1.36B |